USA Solid Tumor Therapeutics Market Size, Share & Forecast 2025-2031

The market was valued at USD 104.8 Bn in 2025 under a net manufacturer and channel revenue lens covering prescription therapeutics used to treat malignant solid tumors. The estimate excludes hematologic malignancies, diagnostics, radiation, surgery, supportive care, and unrelated hospital services. It was triangulated using company-level oncology revenue, treated patient-years, net therapy expenditure, incidence, survivorship, and national cancer medicine spending. Immunotherapies, targeted small molecules, ADCs, endocrine treatments, and chemotherapy are included where they generate U.S. solid-tumor treatment revenue.

The market is forecast to grow at an 8.3% CAGR from 2025 to 2031, reaching USD 169.1 Bn. Growth is expected to peak near 8.7% in 2028 as ADCs, radioligand therapies, earlier-stage immunotherapy, and mutation-selective agents broaden treatment eligibility. Expansion moderates after 2028 because leading checkpoint inhibitor franchises face biosimilar, patent-expiry, and Medicare negotiation pressure. Patient-volume growth remains positive, while price and product-mix growth is sustained by premium precision therapies and combination regimens.

Antibody-drug conjugates, radioligand therapies, mutation-selective small molecules, and earlier-stage immunotherapy represent the fastest-expanding profit pools. ADCs combine platform licensing, premium pricing, multiple tumor targets, and label expansion opportunities. Radioligands create high barriers through isotope production and certified treatment sites. Precision small molecules can address narrow but high-response biomarker populations, while perioperative immunotherapy expands use into larger curative-intent populations. Conventional chemotherapy remains clinically important but generates slower value growth because of generic pricing and supply competition.

The largest risk is simultaneous revenue pressure from Medicare negotiation, patent expiration, biosimilar entry, and higher payer evidence thresholds. Established products with concentrated Medicare exposure can experience abrupt net-price reductions even while clinical demand remains strong. Keytruda's approximately USD 29.5 Bn global sales in 2024 illustrate the concentration risk attached to a major oncology franchise approaching 2028 exclusivity events. Manufacturers also face greater confirmatory-trial requirements and tighter utilization management for expensive combinations.

The United States ranks first among selected major pharmaceutical markets, with modeled 2025 solid-tumor therapeutics revenue more than three times China's. The country benefits from higher medicine spending per patient, rapid FDA-to-market conversion, extensive clinical trial infrastructure, specialty distribution, and broad adoption of newly approved therapies. China is forecast to grow faster from a smaller base, while Japan, Germany, the United Kingdom, and Canada show lower growth because of tighter pricing controls, slower launch uptake, or smaller eligible populations.

The most important demand factor is the combination of high annual incidence and longer survivorship. Approximately 2.04 million new cancer cases were expected in 2025, while 18.6 million people were living as cancer survivors. Longer survival increases maintenance duration, recurrence treatment, and exposure to multiple sequential lines. Growth is therefore not dependent only on additional diagnoses. It also reflects treatment intensity, stage migration, biomarker identification, and the ability to convert previously untreatable populations into addressable therapeutic cohorts.

Commercial scale requires more than FDA approval. A therapy must have identifiable patients, timely biomarker testing, adequate manufacturing capacity, workable reimbursement, provider readiness, specialist distribution, and evidence that supports sequencing within existing standards of care. Radioligand and cellular therapies illustrate how manufacturing and site certification can constrain revenue despite strong clinical demand. ADCs and targeted agents depend on testing coverage and toxicity-management capability. Products with simpler administration, broad labels, and measurable total-care benefits generally achieve faster adoption.